BR9812523A - Processo para preparar um dispositivo de distribuição transdérmica, dispositivo de distribuição transdérmica, e, uso de um esteróide como um aditivo - Google Patents

Processo para preparar um dispositivo de distribuição transdérmica, dispositivo de distribuição transdérmica, e, uso de um esteróide como um aditivo

Info

Publication number
BR9812523A
BR9812523A BR9812523-0A BR9812523A BR9812523A BR 9812523 A BR9812523 A BR 9812523A BR 9812523 A BR9812523 A BR 9812523A BR 9812523 A BR9812523 A BR 9812523A
Authority
BR
Brazil
Prior art keywords
delivery device
steroid
transdermal delivery
additive
preparing
Prior art date
Application number
BR9812523-0A
Other languages
English (en)
Inventor
Fabian Isaac Biali
Alejandro Fabio Scasso
Francisco Jose Evarist Stefano
Original Assignee
Ethical Pharmaceuticals South
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ethical Pharmaceuticals South filed Critical Ethical Pharmaceuticals South
Publication of BR9812523A publication Critical patent/BR9812523A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

"PROCESSO PARA PREPARAR UM DISPOSITIVO DE DISTRIBUIçãO TRANSDéRMICA, DISPOSITIVO DE DISTRIBUIçãO TRANSDéRMICA, E, USO DE UM ESTERóIDE COMO UM ADITIVO" Um esteróide é usado como um aditivo na manufatura de um dispositivo de distribuir droga transdérmica, para atuar como um inibidor de cristalização inibindo cristalização, durante armazenagem do dispositivo, de uma droga ativa na forma de um hormónio que tem um efeito fisiológico ou farmacêutico no uso do dispositivo. O esteróide para inibir cristalização está presente no dispositivo em uma quantidade insuficiente para fornecer significante efeito fisiológico ou farmacêutico no uso do dispositivo.
BR9812523-0A 1997-09-25 1998-09-24 Processo para preparar um dispositivo de distribuição transdérmica, dispositivo de distribuição transdérmica, e, uso de um esteróide como um aditivo BR9812523A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9720470.5A GB9720470D0 (en) 1997-09-25 1997-09-25 Inhibition of crystallization in transdermal devices
PCT/GB1998/002880 WO1999015156A1 (en) 1997-09-25 1998-09-24 Inhibition of crystallization in transdermal devices

Publications (1)

Publication Number Publication Date
BR9812523A true BR9812523A (pt) 2000-07-25

Family

ID=10819670

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9812523-0A BR9812523A (pt) 1997-09-25 1998-09-24 Processo para preparar um dispositivo de distribuição transdérmica, dispositivo de distribuição transdérmica, e, uso de um esteróide como um aditivo

Country Status (8)

Country Link
US (1) US6465005B1 (pt)
EP (1) EP1023055B1 (pt)
AR (1) AR013520A1 (pt)
BR (1) BR9812523A (pt)
DE (1) DE69803592T2 (pt)
ES (1) ES2172195T3 (pt)
GB (1) GB9720470D0 (pt)
WO (1) WO1999015156A1 (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000074661A2 (en) 1999-06-05 2000-12-14 Noven Pharmaceuticals, Inc. Solubility enhancement of drugs in transdermal drug delivery systems and methods of use
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
KR100856523B1 (ko) * 2000-08-03 2008-09-04 안타레스 파르마 아이피엘 에이쥐 충분한 치료효과를 보장하는 활성 화합물의 경피 및/또는경점막 투여용 신규 조성물
WO2002045701A2 (en) * 2000-12-05 2002-06-13 Noven Pharmaceuticals, Inc. Crystallization inhibition of drugs in transdermal drug delivery systems
TWI277418B (en) * 2001-06-18 2007-04-01 Noven Pharma Enhanced drug delivery in transdermal systems
JP2005528432A (ja) * 2002-05-30 2005-09-22 ワトソン ファーマシューティカルズ， インコーポレイテッド ノルエチンドロン徐放処方物およびそれに関連する方法
US20050058695A1 (en) * 2002-05-30 2005-03-17 Watson Pharmaccuticals, Inc. Norethindrone sustained release formulations and methods associated therewith
US7387788B1 (en) 2003-10-10 2008-06-17 Antares Pharma Ipl Ag Pharmaceutical compositions of nicotine and methods of use thereof
JP5619337B2 (ja) * 2003-10-10 2014-11-05 フェリング ビー．ブイ． 皮膚残渣を最小限に抑えるための経皮的医薬製剤
TW200514582A (en) * 2003-10-31 2005-05-01 Hisamitsu Pharmaceutical Co Transdermal preparation and method for reducing side effect in pergolide therapy
US7425340B2 (en) * 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
KR100699582B1 (ko) 2005-07-11 2007-03-23 삼성전기주식회사 출력 버퍼회로
US10137135B2 (en) 2005-08-15 2018-11-27 Allergan Sales, Llc Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith
FR2895679B1 (fr) * 2005-12-29 2012-06-08 Pf Medicament Stabilisation de testosterone au sein de dispositifs transdermiques
CA2646667C (en) 2006-04-21 2014-03-11 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
US20080226698A1 (en) * 2007-03-16 2008-09-18 Mylan Technologies, Inc. Amorphous drug transdermal systems, manufacturing methods, and stabilization
KR20110082142A (ko) * 2008-10-06 2011-07-18 밀란 테크놀로지즈 인코포레이티드 비정질 로티고틴 경피 시스템
CA2854164C (en) * 2011-11-04 2021-04-13 Agile Therapeutics, Inc. Dermal delivery compositions and methods
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
HUE055562T2 (hu) 2011-11-23 2021-11-29 Therapeuticsmd Inc Természetes kombinációjú hormon helyettesítõ kiszerelések, és terápiák ezekkel
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023084A (en) 1986-12-29 1991-06-11 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US4832953A (en) 1987-08-13 1989-05-23 Alza Corporation Method for preventing the formation of a crystalline hydrate in a dispersion of a liquid in a monaqueous matrix
US4906475A (en) 1988-02-16 1990-03-06 Paco Pharmaceutical Services Estradiol transdermal delivery system
DE68917292T2 (de) 1988-02-26 1995-02-02 Riker Laboratories Inc Transdermales estradiol als therapeutisches sytem.
US5223261A (en) 1988-02-26 1993-06-29 Riker Laboratories, Inc. Transdermal estradiol delivery system
US4994267A (en) 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Transdermal acrylic multipolymer drug delivery system
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US4814168A (en) 1988-03-04 1989-03-21 Noven Pharmaceuticals, Inc. Transdermal multipolymer drug delivery system
ZA899112B (en) 1988-12-01 1990-08-29 Schering Corp Compositions for transdermal delivery of estradiol
AR246186A1 (es) 1989-11-17 1994-07-29 Beta Pharm Co Procedimiento para fabricar un dispositivo para administrar estradiol por via transdermica.
GB9021674D0 (en) 1990-10-05 1990-11-21 Ethical Pharma Ltd Transdermal device
US5518734A (en) 1991-09-25 1996-05-21 Beta Pharmaceuticals Co. Transdermal delivery system for estradiol and process for manufacturing said device
DE4210711A1 (de) * 1991-10-31 1993-05-06 Schering Ag Berlin Und Bergkamen, 1000 Berlin, De Transdermale therapeutische systeme mit kristallisationsinhibitoren
US5676968A (en) * 1991-10-31 1997-10-14 Schering Aktiengesellschaft Transdermal therapeutic systems with crystallization inhibitors
US5460820B1 (en) * 1993-08-03 1999-08-03 Theratech Inc Method for providing testosterone and optionally estrogen replacement therapy to women
DE4405898A1 (de) 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
DE4429664C2 (de) 1994-08-20 1997-09-11 Lohmann Therapie Syst Lts Estradiol-TTS mit wasserbindenden Zusätzen und Verfahren zu seiner Herstellung
US5906830A (en) * 1995-09-08 1999-05-25 Cygnus, Inc. Supersaturated transdermal drug delivery systems, and methods for manufacturing the same

Also Published As

Publication number Publication date
EP1023055A1 (en) 2000-08-02
DE69803592D1 (de) 2002-03-14
GB9720470D0 (en) 1997-11-26
US6465005B1 (en) 2002-10-15
ES2172195T3 (es) 2002-09-16
AR013520A1 (es) 2000-12-27
EP1023055B1 (en) 2002-01-23
DE69803592T2 (de) 2002-09-19
WO1999015156B1 (en) 1999-06-10
WO1999015156A1 (en) 1999-04-01

Similar Documents

Publication Publication Date Title
BR9812523A (pt) Processo para preparar um dispositivo de distribuição transdérmica, dispositivo de distribuição transdérmica, e, uso de um esteróide como um aditivo
PT768867E (pt) Forma de dosagem para a administracao de droga em formulacao liquida
BR0014929A (pt) Dispositivo para distribuição de medicamento, e, processo para distribuir um agente farmaceuticamente ativo para um tecido alvo dentro de um corpo
BR0107869A (pt) Composições farmacêuticas eletrogiradas
ES2139132T3 (es) Composiciones farmaceuticas activas en la terapia de desordenes del sueño.
ES2093747T3 (es) Composicion farmaceutica que contiene felbinac.
DE60027463D1 (de) Pharmazeutische zusammensetzungen enthaltend resveratrol und verwendungen davon
AR025763A1 (es) Metodos y sistemas para el tratamiento del tejido enfermo con composiciones antiinfecciosas
DE69718037D1 (de) Penetrationsfördernde substanzen für die transdermale verabreichung von wirkstoffen, vorrichtungen und verfahren zur herstellung
PT1246625E (pt) Utilizacoes e composicoes de esteres de nitrato para proporcionar sedacao
BR0012082A (pt) Formulação farmacêutica para administração compreendendo morfina e seu uso
DE60112102D1 (de) Kombination aus einem no-donor und einem antioxidans zur behanndlung sexueller störungen
MX9606502A (es) Composiciones antiqueratoliticas y curativas para heridas y metodos para preparar y utilizar las mismas.
NO952906D0 (no) Farmasöytisk formulering for behandling av nikotinavhengighet
NZ332215A (en) Transdermally administered dextromethorphan as antitussive agent
EP0137543A3 (en) Pharmaceutical composition for the therapy of peripheral arteriopathies
PE123899A1 (es) Formulacion que contiene un opioide en combinacion con un agonista alfa-adrenergico y su utilizacion como analgesico
BR0008057A (pt) Forma cristalina de eplerenona apresentando velocidade de dissolução intensificada
ATE22879T1 (de) Pharmazeutische zusammensetzungen und verfahren zu deren herstellung.
BR0207866A (pt) Uso de flumazenil na preparação de um medicamento para o tratamento da dependência de cocaìna
KR970703142A (ko) 신전성 선조를 치료하기 위해 알파 히드록시산을 도포시키는 방법(applying alpha hydroxy acids for striae distensae)
ATE353224T1 (de) Abgabeeinrichtung für eine zusammensetzung einer pharmazeutisch wirksamen substanz
BRPI0417530B8 (pt) composição para a liberação transdérmica de hormônios sem a necessidade de melhoradores de penetração, sistema terapêutico transdérmico, e kit
CO5130011A1 (es) Nuevos usos farmaceuticos para inhibidores nos
ES2151075T3 (es) Tabletas de esteroides de baja dosificacion, que contienen esteres de acido galico como antioxidante, proceso para su fabricacion y utilizacion.

Legal Events

Date Code Title Description
TC Change of name
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]